Loading…
Lobbying Spend
—
Filings
31
Firms Hired
1
Active Period
2019–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
2025 · fourth_quarter · Firm: MARSHALL & POPP, LLC
Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the regulation of hemp-derived cannabinoids, including H.R.4121/S.2256 - FY26 Agriculture, FDA and Related Agencies Appropriations, and H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026. H.R.946 - ORPHAN Cures Act.
Client expense: — · Firm income: $40,000
Matched citations: H.R.4121
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
2025 · fourth_quarter · Firm: MARSHALL & POPP, LLC
Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the regulation of hemp-derived cannabinoids, including H.R.4121/S.2256 - FY26 Agriculture, FDA and Related Agencies Appropriations, and H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026. H.R.946 - ORPHAN Cures Act.
Client expense: — · Firm income: $40,000
Matched citations: H.R.5371
Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the regulation of hemp-derived cannabinoids, including H.R.4121/S.2256 - FY26 Agriculture, FDA and Related Agencies Appropriations, and H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026. H.R.946 - ORPHAN Cures Act.
Client expense: — · Firm income: $40,000
Matched citations: H.R.946
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
2025 · fourth_quarter · Firm: MARSHALL & POPP, LLC
Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the regulation of hemp-derived cannabinoids, including H.R.4121/S.2256 - FY26 Agriculture, FDA and Related Agencies Appropriations, and H.R.5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026. H.R.946 - ORPHAN Cures Act.
Client expense: — · Firm income: $40,000
Matched citations: S.2256
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
2025 · third_quarter · Firm: MARSHALL & POPP, LLC
Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the regulation of hemp-derived cannabinoids, including H.R.4121/S.2256 - FY26 Agriculture, FDA and Related Agencies Appropriations. H.R.946 - ORPHAN Cures Act.
Client expense: — · Firm income: $40,000
Matched citations: H.R.4121
Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the regulation of hemp-derived cannabinoids, including H.R.4121/S.2256 - FY26 Agriculture, FDA and Related Agencies Appropriations. H.R.946 - ORPHAN Cures Act.
Client expense: — · Firm income: $40,000
Matched citations: H.R.946
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
2025 · third_quarter · Firm: MARSHALL & POPP, LLC
Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the regulation of hemp-derived cannabinoids, including H.R.4121/S.2256 - FY26 Agriculture, FDA and Related Agencies Appropriations. H.R.946 - ORPHAN Cures Act.
Client expense: — · Firm income: $40,000
Matched citations: S.2256
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
2025 · second_quarter · Firm: MARSHALL & POPP, LLC
Issues related to budget reconciliation, including H.Con.Res. 14.
Client expense: — · Firm income: $40,000
Matched citations: H.Con.Res. 14
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · second_quarter · Firm: MARSHALL & POPP, LLC
Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including H.R. 1, FY25 budget reconciliation, implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the regulation of hemp-derived cannabinoids, including H.R. 4121, FY26 Agriculture, FDA and Related Agencies Appropriations. H.R.946 - ORPHAN Cures Act.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 1
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
2025 · second_quarter · Firm: MARSHALL & POPP, LLC
Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including H.R. 1, FY25 budget reconciliation, implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the regulation of hemp-derived cannabinoids, including H.R. 4121, FY26 Agriculture, FDA and Related Agencies Appropriations. H.R.946 - ORPHAN Cures Act.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 4121
Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including H.R. 1, FY25 budget reconciliation, implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the regulation of hemp-derived cannabinoids, including H.R. 4121, FY26 Agriculture, FDA and Related Agencies Appropriations. H.R.946 - ORPHAN Cures Act.
Client expense: — · Firm income: $40,000
Matched citations: H.R.946
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
2025 · first_quarter · Firm: MARSHALL & POPP, LLC
Issues related to budget reconciliation, including H.Con.Res. 14 and S.Con.Res. 7.
Client expense: — · Firm income: $40,000
Matched citations: H.Con.Res. 14
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2025 · first_quarter · Firm: MARSHALL & POPP, LLC
Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 946, Orphan Cures Act; and implementation of the Inflation Reduction Act (PL 117-169). Issues related to the regulation of hemp-derived cannabinoids. H.R.946 - ORPHAN Cures Act.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 1492
Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 946, Orphan Cures Act; and implementation of the Inflation Reduction Act (PL 117-169). Issues related to the regulation of hemp-derived cannabinoids. H.R.946 - ORPHAN Cures Act.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 946, H.R.946
An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
2025 · first_quarter · Firm: MARSHALL & POPP, LLC
Issues related to budget reconciliation, including H.Con.Res. 14 and S.Con.Res. 7.
Client expense: — · Firm income: $40,000
Matched citations: S.Con.Res. 7
Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to the regulation of hemp-derived cannabinoids, including FY25 Agriculture, FDA and Related Agencies Appropriations and H.R. 8467, the Farm, Food, and National Security Act of 2024. H.R.10545, FY25 Continuing Appropriations.
Client expense: — · Firm income: $40,000
Matched citations: H.R.10545
S. 2860 / S. 1323 / HR 2891, SAFE Banking Act, issues related to the definition of business of insurance.
Client expense: — · Firm income: $40,000
Matched citations: HR 2891
Farm, Food, and National Security Act of 2024
2024 · fourth_quarter · Firm: MARSHALL & POPP, LLC
Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to the regulation of hemp-derived cannabinoids, including FY25 Agriculture, FDA and Related Agencies Appropriations and H.R. 8467, the Farm, Food, and National Security Act of 2024. H.R.10545, FY25 Continuing Appropriations.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 8467
S. 2860 / S. 1323 / HR 2891, SAFE Banking Act, issues related to the definition of business of insurance.
Client expense: — · Firm income: $40,000
Matched citations: S. 1323
S. 2860 / S. 1323 / HR 2891, SAFE Banking Act, issues related to the definition of business of insurance.
Client expense: — · Firm income: $40,000
Matched citations: S. 2860
S. 2860 / S. 1323 / HR 2891, SAFE Banking Act, issues related to the definition of business of insurance.
Client expense: — · Firm income: $40,000
Matched citations: HR 2891
Farm, Food, and National Security Act of 2024
2024 · third_quarter · Firm: MARSHALL & POPP, LLC
Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to the regulation of hemp-derived cannabinoids, including FY25 Agriculture, FDA and Related Agencies Appropriations and H.R. 8467, the Farm, Food, and National Security Act of 2024.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 8467
S. 2860 / S. 1323 / HR 2891, SAFE Banking Act, issues related to the definition of business of insurance.
Client expense: — · Firm income: $40,000
Matched citations: S. 1323
S. 2860 / S. 1323 / HR 2891, SAFE Banking Act, issues related to the definition of business of insurance.
Client expense: — · Firm income: $40,000
Matched citations: S. 2860
S. 2860 / S. 1323 / HR 2891, SAFE Banking Act, issues related to the definition of business of insurance.
Client expense: — · Firm income: $40,000
Matched citations: HR 2891
Source: Senate LDA